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Since  the  introduction  of biological  therapy,  endoscopic  and  histological  remission,  i.e. mucosal  healing,
has  become  an  important  therapeutic  goal  in Crohn’s  Disease  and  Ulcerative  Colitis.  Mucosal  healing  is
associated  with lower  rates  of  hospitalization  and  surgery,  although  its  role  in preventing  progression
and  changing  the natural  history  of the  disease  has not  been  clearly  demonstrated.  A precise  deﬁnition  of
mucosal  healing  has not  yet  been  established,  although  the concept  used  in clinical  trials  is the  “complete
absence  of all inﬂammatory  and  ulcerative  lesions  in all segments  of  gut”  at  endoscopy.  This  deﬁnition
does  not  include  mucosal  improvement  and  does  not  distinguish  among  grades  of mucosal  healing.  In
both  Crohn’s  Disease  and  Ulcerative  Colitis  trials, several  qualitative  and  quantitative  numeric  endoscopicucosal healing
athology
indices  have  been  proposed  to  measure  and  distinguish  endoscopic  changes.  In addition,  the  microscopic
features  associated  with  inﬂammatory  bowel  diseases  are  considerably  modiﬁed  by the  course  of the
disease  and  the  treatments  adopted.  However,  it is not  yet  clear  whether  microscopic  healing  should  be
a primary  endpoint  in  clinical  trials.  In this  paper  we discuss  endoscopic  and  histological  ﬁndings  and  the
limitations  of  the  endoscopic  and  histological  indices  as  a basis  for a standardised  diagnosis  of  mucosal
healing.
 Gast© 2013 Editrice
. Introduction
In recent years the management of inﬂammatory bowel dis-
ases (IBD) has substantially changed, due to the fact that the new
reatments with anti-TNF drugs induce not only clinical remis-
ion but also a signiﬁcant endoscopic improvement, or even a
otal disappearance of the intestinal lesions [1]. Although conven-
ional therapies with 5-aminosalicylic acid (5-ASA), oral steroids
nd immunomodulators may  lead to mucosal healing (MH), the MH
ate with these agents is lower than that obtained with anti-TNF
2–7]. At present, there is signiﬁcant evidence that the use of anti-
NF drugs, such as inﬂiximab, adalimumab, and certolizumab
egol, can induce and sustain endoscopic healing [8,9]. The mech-
nisms of action of the anti-TNF therapies are largely unknown.
ery recently, in 2 in vivo models Fischer found that adalimumab
revents intestinal barrier dysfunction and antagonises distinct
ffects of TNF on tight junction proteins and signalling pathways in
ntestinal epithelial cells. All these events may  therefore represent
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San Nicola Pellegrino” Hospital, 76125 Trani, BT, Italy. Tel.: +39 0883 483209;
ax: +39 0883 483342.
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a novel mechanism of action whereby antiTNF drugs participate in
epithelial and tissue repair in CD and UC [10].
MH has now become an important endpoint to assess the ther-
apeutic effect in IBD [11–13]. The deﬁnition of MH currently used
in CD and UC clinical trials is the “complete absence of all inﬂam-
matory and ulcerative lesions”, but this deﬁnition lacks validation
and does not include mucosal improvement and grading of MH
[11,14–16]. Furthermore, in most studies the deﬁnition of MH in
UC includes the presence of “persistent erythema and friability at
endoscopy” without ulceration or erosions [14].
The aim of this paper is to review different deﬁnitions of endo-
scopic healing and to describe the endoscopic indices commonly
used in clinical trials. We  also point out the role of histological
assessment and the need to use a standardised validated endo-
scopic score to avoid differences in MH  rates among the various
trials.
1.1. Controversies in MH deﬁnition
Controversies regarding the currently available deﬁnitions of
MH are shown in Tables 1 and 2, reporting endoscopic indices,
endoscopic features, MH  deﬁnition, time/weeks between endo-
scopic re-evaluations and the percentage of patients showing MH.
The different deﬁnitions of MH,  such as “absence of ulcers” or
 Ltd. All rights reserved.
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Table  1
Endoscopic indices used in Crohn’s disease and ulcerative colitis.
Endoscopic features Range Proposed MH cut-off Validated predictive
cut-off
CD endoscopic indices
Crohn’s Disease Endoscopic Index of
Severity (CDEIS) (1989)
Presence or absence of ulcers
(superﬁcial or deep); percentage of
ulcerated or inﬂamed surface, stenosis
(ulcerated or non ulcerated) in ﬁve
intestinal segments
0–44 CDEIS > 3 CDEIS 0(42–46) –
Simpliﬁed Endoscopic Activity Score
for Crohn’s Disease (SES-CD) (2004)
Presence or absence of ulcers (size);
proportion of the intestinal surface
affected by ulcerations and by other
inﬂammatory lesions; narrowing
(single or multiple and permitting





Rutgeert’s score (1990) Presence of ulcers, diffuse
inﬂammation and ulcers, nodules
and/or narrowing
0–4 Rutgeert 0–1(42–46) 3–4 relapse
Lemman score (2011) Presence of stricture lesions and
presence of penetrating lesions
0–10 – –
UC  endoscopic indices
Truelove and Witts (1955) Hyperemia and granularity 0–3 – –
Baron score (1964) Severity of mucosal bleeding and
friability
0–3 – –
Modiﬁed Baron Score (1964) Vascular pattern; mucosal granularity;
bleeding, mucus, ﬁbrin, erosions and
ulcers
0–4 – –
Powell-Tuck score (1978) Severity of mucosal bleeding and
friability
0–2 – –
Sutherland score (1987) Severity of mucosal bleeding and
friability
0–2 – –
Rachmilewitz score (1989) Vascular pattern; mucosal granularity;
bleeding, mucus, ﬁbrin, erosions and
ulcer
0–12 – –
Mayo  score (1987) Erythema, vascular pattern, friability,
erosions, spontaneous bleeding,
ulcerations
0–3 0–1 (56) –
Ulcerative Colitis Endoscopic Index
of  Severity (UCEIS) (2011)





Bleeding (none, mucosal, luminal mild,
luminal moderate or severe);
Lesions (none, erosions, superﬁcial
ulcers, deep ulcers)
0–4 for bleeding and
lesions
Ulcerative Colitis Colonoscopy Index
of Severity (UCCIS) (2013)
Vascular pattern (normal, partially
visible, complete loss); Granularity
(normal, ﬁne, coarse); Ulceration
(normal, erosions or pinpoint
ulcerations, shallow ulcers with
mucopus, deep ulcerations, diffuse
ulcerated with >30% involvement);
Bleeding/friability (normal, friable and






















rH,  mucosal healing.
endoscopic scores improvement”, as well as the duration of the
iological therapy certainly interfere with the rate of MH.  In fact,
n CD patients the short-term re-evaluation at 10 weeks demon-
trated an “absence of ulcers” ranging between 11% and 29% of
atients, and this rate rose to 45%, 44%, and 73% when patients
nderwent endoscopy at 24–54 and 104 weeks. Instead, when MH
as considered as an “endoscopic scores improvement”, the short-
erm MH  rate at endoscopic re-evaluation ranged between 64% and
0% and remained at the same rate after medium and long-term
reatment. In UC patients, the endoscopic short-term re-evaluation
evealed a diagnosis of MH  as “absence of ulcers” (MAYO 0) in about
7% of the patients, on the contrary when MH  was considered as the
endoscopic scores improvement” (MAYO 1) the rate of MH  ranged
etween 30% and 62% both in short- and long-term endoscopic
e-evaluations.The importance of achieving MH  in clinical practice is correlated
to recent evidence that shows that MH  is associated with long-term
symptomatic remission and a longer relapse-free interval [17], as
well as with a reduction in the frequency of hospitalizations, com-
plications and surgical resections [18–20], and with a signiﬁcant
improvement of quality of life [21]. Furthermore, MH  is associ-
ated to a reduction of cancer risk and cancer-related mortality;
data suggest that colorectal cancer in IBD patients is driven by a
persistent active inﬂammation. Controlled prospective studies are
lacking but a large cohort study indicates a lower risk of colorectal
cancer in the presence of MH  in patients treated with azathioprine
[22] and inﬂiximab [23]. All these events seem to have a prognostic
relevance, but the role of MH  in preventing progression and chang-
ing the natural history of IBD has never been demonstrated [24]
probably due to the late use of anti-TNF drugs.
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Table 2
Mucosal healing deﬁnition and endoscopic timing in clinical trials and anti-TNF .
Authors Study design Patients Disease Evaluation of MH MH%  Endoscopic
timing/weeks
Van Dullemen (1995) Open-label study with a single IFX
infusion
10 CD Improvement of CDEIS (no
deﬁnition of MH)
90 4
D’Haens (1999) Multicenter randomised double
blind with a single IFX infusion (5,
10, 20 mg/kg)
30 CD Improvement of CDEIS (No
deﬁnition of MH)
Non reported 4
Rutgeerts (2006) Multicenter randomised controlled
trial Inducing and scheduled IFX vs.
episodic infusion (ACCENT I)
99/573 CD Absence of mucosal ulcerations 29 vs. 3 10
44 vs. 18 54
CDEIS improvement 76 10
93 54
D’Haens (2008) Open-label randomised trial 49/133 CD Absence of mucosal ulcerations
(SES CD 0).
73 104
Early  combinational therapy with




Schnitzler (2009) Observational study with
scheduled IFX
214/614 CD Complete MH (absence of
ulceration)
45 24




Colombel (2008) Multicenter randomised controlled
trial
309/508 CD Absence of mucosal ulcerations
(No score)
16 26
AZA  + placebo IFX + placebo
IFX + AZA (SONIC)
30
44
Colombel (2010) Multicenter Open label study with
Certolizumab pegol (MUSIC)
89 CD Absence of ulcers 5 10









CDEIS <7 (endoscopic remission) 28 54
Rutgeerts (2009) Randomised placebo-controlled
trial with ADA (EXTENT)





Improvement of lesions: CDEIS <4 28 52
SES CD <5
Rutgeerts (2005) Multicenter Randomised,
double-blind placebo-controlled
trial with IFX (ACT1–ACT2)
726 UC ACT1 (Mayo 0–1) 62 8
50 30
45 54
ACT2 (Mayo 0–1) 60 8
Mayo 0 46 30
27 8
Aﬁf  (2009) Uncontrolled Open label study
with ADA
20 UC Mayo 0–1 30 8
Reinisch (2011) Multicenter Randomised,
double-blind placebo- controlled
trial with ADA
390 UC Mayo 0–1 47 8









oH,  mucosal healing.
. Role of endoscopy
Ileocolonoscopy in IBD patients is used to: (i) diagnose CD and
C; (ii) predict an aggressive course of disease; (iii) obtain biopsies
f the intestinal mucosa for histological examination; (iv) moni-
or dysplasia and the risk of colorectal cancer [25]. In the last few
ears a new important role of ileocolonoscopy has emerged in the
valuation of the mucosal response to therapy, i.e. the grade of MH.
Correlations between histological disease activity and
ndoscopy are fairly good, especially when the samples are
btained during active inﬂammation, even though microscopic25 52
features of activity may  persist in a macroscopically inactive
disease [26]. Modern sophisticated techniques, such as confocal
laser endomicroscopy (CLE) and chromoendoscopy (CE), have
been proposed to provide a more detailed view of the mucosa
[27,28] for assessing mucosal and histological healing and for the
detection of intraepithelial neoplasia [29]. The potential role of
CLE in the management of IBD patients is based on its capacity to
evaluate, in vivo, the structural healing of chronic inﬂammation
in IBD: crypt and vessel architecture, and cellular inﬁltration
[30,31]. Recently, a classiﬁcation of activity inﬂammation in UC
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LE images might offer information equivalent to conventional
istology, with a good correlation between CLE and histological
esults. In particular, CLE is also able to assess MH after treatment
ith biological agents [33] and to predict disease outcome [34,35].
peciﬁc patterns observed with CE may  be important for the
dentiﬁcation of dysplasia during surveillance of UC [36] and CD
atients [37] and for the diagnosis of intraepithelial neoplasia [38].
eumann [39] recently developed an endomicroscopic activity
ndex, denoted “Crohn’s Disease Endomicroscopic Activity Score”,
o graduate the severity of inﬂammation in this disease. This score
s the ﬁrst endoscopic index for Crohn’s disease based on in vivo
istology, but its validity has still to be conﬁrmed. The Watson
core [40] is another scoring system based on functional in vivo
maging that may  be used to predict clinical relapse. A clinical trial
s now ongoing to analyse the mechanism of action of inﬂiximab
t the CLE level and to analyse MH,  i.e. structural and functional
hanges in the mucosa in IBD patients [41].
. Endoscopic scores in the era of MH
The need to evaluate MH has conﬁrmed the function of
ndoscopy in the management and follow-up of IBD patients. For
his reason, endoscopic scores used to classify disease activity
11,12] have also been proposed to deﬁne MH in CD and UC. The
ain problem in the use of endoscopic scores is that many of these
re complex and time-consuming. Another important limitation
s the absence of: (a) a validated deﬁnition of MH;  (b) guidelines
or the correct and optimal timing of endoscopic re-evaluation
uring therapy; (c) agreement about cutoff values of endoscopic
cores to measure MH and deﬁne endoscopic response or remis-
ion. Furthermore, the limited ability of conventional endoscopy
o evaluate disease activity in the small bowel means that other
ools are needed, such as capsule endoscopy or enteroscopy. The
CCO guidelines state that small bowel capsule endoscopy has an
mportant role in the assessment of mucosal lesions or MH.  How-
ver, also in this area there are no validated endoscopic indices to
eﬁne remission and guide medical decision-making [42].
.1. Endoscopic scores in Crohn’s disease
The ﬁrst endoscopic score for evaluating the severity of ileo-
olonic lesions in CD was the Crohn’s Disease Endoscopic Index of
everity (CDEIS), developed and validated by the Groupe d’Etudes
hérapeutiques des Affections Inﬂammatoires Digestives (GETAID)
n France [43]. This numerical score ranges between 0 and 44
nd evaluates, in 5 bowel segments (terminal ileum, right colon,
ransverse, left colon and sigmoid, and rectum) on a 10-cm linear
cale, the following features: (i) the presence or absence of ulcers,
istinguished as superﬁcial or deep; (ii) the presence of steno-
is, classiﬁed as ulcerated or non-ulcerated; and (iii) the surface
xtension of disease activity, classiﬁed as ulceration or only inﬂam-
ation. The score requires prior training but is highly reproducible
mong different operators. The time-consuming surface measure-
ent technique (usually performed on previously recorded videos)
s probably the main reason why CDEIS is only used in clinical trials
nd not in clinical practice. Recently, a new, simpler endoscopic
core was developed by Daperno et al. [44]. This score, named
Simpliﬁed Endoscopic Activity Score for Crohn’s Disease” (SES-
D), ranges from 0 to 60 and includes 4 variables: (i) the intestinal
urface affected by ulcers; (ii) the intestinal surface affected by
ther inﬂammatory lesions; (iii) the presence of ulcers; (iv) the
resence of narrowing (differentiated as single or multiple and per-
itting passage or not). Each of these variables is scored from 0
o 3 and evaluated in 5 intestinal segments (terminal ileum, right
olon, transverse, left colon and sigmoid, and rectum). In this scorer Disease 45 (2013) 969– 977
the presence of ulcers is classiﬁed not as deep or superﬁcial but
according to size (0.1–0.5 cm;  0.5–2 cm;  >2 cm), and ulcerated sur-
faces and intestinal surfaces affected by other inﬂammatory lesions
are classiﬁed according to their extension (<10%; 10–30%; >30%);
(<50%; 50–75%; >75%). A correlation between the SES-CD and the
CDEIS [44], and between the SES-CD and clinical and laboratory
parameters [44] has been reported. Fig. 1 shows representative
images (A, B, C) from different endoscopic scenarios induced by
biological therapy in a CD patient.
In CD patients undergoing surgery, literature data demonstrate
that disease recurrence is frequent and that 90% of patients have
new endoscopic lesions as early as 1 year after surgery [45]. A
validated endoscopic index (Rutgeert’s score [46]) measures endo-
scopic recurrence in the neo-terminal ileum and/or ileocolonic
anastomosis. This score ranges from 0 to 4, classiﬁed as: (0) absence
of lesions; (1) <5 aphthous lesions, (2) >5 more severe aphthous
lesions; (3) diffuse inﬂammation with diffuse ulcers; (4) nodules
and/or narrowing. The Rutgeert’s score is the gold standard for the
prognosis of postoperative recurrence; indeed, scores 3 and 4 are
validated cutoff values that predict clinical relapse [47]. For this rea-
son ileocolonoscopy is recommended within 1 year after surgical
resection to orient treatment decision-making [48,49].
All the above endoscopic scores explore only the mucosal sur-
face in CD but do not assess transmural injury and penetrating
evolution, signs of progressive disease and structural bowel dam-
age. Today, the important concept of “cumulative bowel damage”
has emerged, and it has been included in a new index called
“The Lemann score” (Crohn’s Disease Digestive Damage Score). The
Lemann score is a complex score that evaluates, in different gas-
trointestinal locations (upper gastrointestinal tract, small bowel,
colon or rectum, and anal or perianal), strictures and penetrat-
ing lesions (ulceration, ﬁstula, and abscess), as well as surgical
resection or bypass of the bowel. Upper gastrointestinal endoscopy,
colonoscopy, Computed Tomography Enterography (CTE) and Mag-
netic Resonance Imaging Enterography (MRE) are the methods
used to assess transmural intestinal damage in the Lemman score.
CTE and MRE  visualise the precise site of intestinal lesions, mesen-
teric changes, and the presence of strictures, ﬁstulae or abscesses,
thus improving the detection of structural small bowel lesions. For
each gastrointestinal segment, disease severity is scored from 0
(normal bowel with no history of surgery) to 3 (including progres-
sive structural bowel lesions and resection). The Lemman score
ranges from 0 (absence of damage) to 10 (complete resection of
the gastrointestinal tract) [50]. This index has been developed to
identify CD patients at high or low risk of rapid damage progression
who would beneﬁt from early biological treatment.
3.2. Endoscopic scores in UC
Numerous scores have been used for the assessment of endo-
scopic activity in UC. The ﬁrst endoscopic score to evaluate disease
activity in UC was proposed by Truelove and Witts [51]. With
this score, the sigmoidoscopic appearance before and after corti-
costeroid treatment was classiﬁed on the basis of hyperaemia and
mucosa granularity. In 1964, Baron [52] described endoscopic dis-
ease activity based only on the severity of bleeding and friability,
while ulceration or other lesions were not considered. This score
ranged from 0 to 4 and distinguished normal mucosa, abnormal
but not haemorrhagic mucosa, moderately haemorrhagic mucosa
with bleeding on contact, and severely haemorrhagic mucosa with
spontaneous bleeding. The Powell-Tuck sigmoidoscopic score [53]
and Sutherland score [54], with ranges 0–2, focused on endo-
scopic evaluation only by assessing bleeding without considering
the presence of other inﬂammatory lesions. Subsequent endoscopic
indices have included the presence of erosions, mucopus, gran-
ularity, and ulcers. In the Rachmilewitz Endoscopic score [55] 4
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Fig. 1. Three different images from a patient with Crohn’s Disease (panels A, B, C) and a patient with Ulcerative Colitis (panels D, E, F) during biological treatments. Panel A:
SES-CD  23 (right, transverse, left colon and rectum involvement with large ulcers involving more than 30% of the intestinal surface and with an affected surface of between
50%  and 75%). Panel B: SES-CD 6 (affected colon surface less than 50% and ulcerative surface less than 10% and aphthous ulcers in left colon). Panel C: SES-CD 0 (mucosal



































iith  marked erythema, friability, erosions and absent vascular patterns. Panel F: M
tems are included: vascular pattern, mucosal granularity, contact
r spontaneous mucosal bleeding, and mucosal damage (mucus,
brin, erosions and ulcer). This score ranges from 0 to 12. A cut-
ff value for remission is also deﬁned. In a prospective study [56] a
igniﬁcant correlation between the Rachmilewitz Endoscopic score
nd clinical and laboratory activity indices was found, identifying
he following cutoffs: (i) inactive disease with score 0–4; (ii) mild
ctivity with score 4–6; (iii) moderate activity with score 7–9; (iv)
igh activity with score 10–12. To date, the Mayo sub-score [57]
s the score system most widely used in clinical trials to describe
he degree of endoscopic activity. The Mayo score is a composite
ndex that includes 4 sub-scores: stool frequency, rectal bleeding,
ndoscopic ﬁndings, physician’s global assessment. Each of these
ub-scores ranges from 0 to 3, while the Mayo score ranges from 0
o 12. A score ≤2 means remission, 3–5 indicates mild disease, 6–10
ndicates moderate disease, and 11–12 indicates severe disease.
he Mayo endoscopic sub-score ranges from 0 to 3: (0) inac-
ive disease and normal mucosa; (1) mild disease (erythema and
ild friability); (2) moderate disease (marked erythema, absent
ascular pattern, friability, erosions), (3) severe disease (sponta-
eous bleeding and diffuse ulceration). The limit of this score is
hat it does not distinguish between deep and superﬁcial ulcera-
ions. In clinical trials and practice, a Mayo endoscopic sub-score
f 0 or 1 is a commonly accepted criterion for MH [14] and, as
ar as avoiding colectomy is concerned, it predicts a better out-
ome than a Mayo sub-score of 2–3. More recently, another score
ndex has been proposed to measure endoscopic severity in UC.
his score, named “Ulcerative Colitis Endoscopic Index of Sever-
ty” (UCEIS), includes 3 variables: (i) vascular pattern (normal = 1,
atchy obliteration = 2; complete obliteration = 3); (ii) bleeding
none = 1, mucosal = 2, luminal mild = 3, luminal severe = 4); (iii)
rosions and ulcers (none = 1, erosions = 2, superﬁcial ulcers = 3,
eep ulcers = 4) [58]. This score was developed as a validated
ndex of endoscopic severity, although the sensitivity of thedoscopic score = 0; mucosal healing.
index to a speciﬁc change, and the threshold for MH,  have yet
to be determined. The correlations of this index need further
investigation before its application in clinical trials and clinical
practice.
Recently, the Ulcerative Colitis Colonoscopic Index of Severity
(UCCIS) has been validated in a prospective cohort of UC patients
[59]. This score is a composite index that includes 4 variables:
vascular pattern, granularity, ulceration, bleeding/friability and
severity of damage in each colon segment and overall. The global
assessment of endoscopic severity is based on a 4-point scale and
a 10-cm visual analogue scale.
Table 1 summarises the endoscopic scores used in CD and UC.
Fig. 1 shows representative images (D, E, F) of different endoscopic
scenarios induced by biological therapy in a UC patient.
4. Histological features
4.1. Basic histopathological concepts
Like in other pathological conditions involving the large bowel,
the pathologist should receive an adequate number of biopsies, cor-
rectly oriented from at least 5 sites (including the rectum and the
terminal ileum). The biopsies should always be accompanied by a
clinical report, including patient age, duration of the disease and
duration and type of treatment [60].
The diagnostic elements for histological assessment are:
a) UC [61]:- Architecture of the crypts: crypt branching, mucosal (crypt) dis-
tortion, decreased crypt density, irregular mucosal surface;
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) CD [62]:
 Architecture of the crypts: segmental crypt atrophy and distor-
tion;
 Lamina propria cellularity: granulomas, segmental inﬂammation,
basal plasmacytosis.
The diagnostic value of the histological features of UC and CD,
nd the differences between the 2 diseases have been extensively
tudied [63]. Crypt architectural abnormalities in the colon are
ore common in UC (57–100% of cases) than CD (27–71% of cases).
ncreased basal lamina propria cellularity and basal plasmacytosis
re common in both UC and CD (76–92% and 72–81%, respectively).
rypt abscesses are more common in UC (41%) than CD (19%), while
ranulomas are characteristic of CD, being present in 21–37% of
iopsy specimens [64]. Basal plasmacytosis is present in more than
0% of IBD patients [65], in 38% of patients with symptoms for less
han 2 weeks, and has disappeared in 50% of IBD patients without
elapse, by 1 year after the onset of colitis [66].
Although no standardised criteria for histological response in
BD patients following therapy are available, the presence of basal
lasmacytosis in quiescent UC seems to be associated with a shorter
isease relapse time [67]. It is also important to consider that an
ndoscopic description of MH  does not necessarily imply histolog-
cal healing of the mucosa [68].
.2. Effects of drugs on histological disease activity
In most of the available studies the evaluation of histological
isease activity was not a treatment endpoint. Moreover, the end-
oints for histological remission of disease for each patient were
ot deﬁned, therefore data on this topic are relatively scarce.
.2.1. Salicylates
In a double-blind, multicentre trial Kruis et al. [69] evaluated
 different doses of 5-aminosalicylic acid (0.5 g three times/day,
.0 g three times/day, and 1.5 g three times/day) in 321 active UC
atients for 8 weeks. Histological improvement was  deﬁned as a
eduction of the histological activity index (HI) by at least 1 point.
ata analysis showed that the 3.0 g/day dose had a higher rate of
ndoscopic improvement (84%) as compared to the 1.5 g/day (53%)
nd 4.5 g/day (70%) doses, but the histological improvement rates
ere lower. The safety and efﬁcacy of balsalazide (6.75 g daily), or
ulfasalazine (3 g daily) were compared in an 8-week randomised,
ulticentre, double-blind, parallel group study that included 50
atients with mild to moderate UC [70]. The trial medication was
he sole treatment and the efﬁcacy was scored by symptom assess-
ent, sigmoidoscopic appearance, and histology (rectal biopsies,
erformed at enrolment and at the ﬁnal visit). Each biopsy was
raded on a 4-point scale (normal to severe inﬂammation) and
ll the patients included in the study had at least mild inﬂamma-
ion at entry (58% severe inﬂammation). In this study, the inclusion
f histology in the assessment of efﬁcacy was meant to identify
atients in whom clinical remission was associated with histolog-
cal remission. After treatment, an improvement was observed in
oth groups; 61% of the patients taking balsalazide achieved clin-
cal and sigmoidoscopic remission. Similarly, an improvement of
istological grades was seen with both treatments and the number
f patients with normal mucosa or minimal inﬂammation without
ctive disease increased in both groups. In another study, Kruis et al.
tudied the efﬁcacy and safety of 2 different treatment dosages (3 g
nce daily or 1 g three times a day) of mesalazine granules in 380 UC
atients [71]. Endoscopy and histology were performed at baseline
nd the ﬁnal visit (8 weeks), the total histological index being based
n the most severely inﬂamed segment. Endoscopic remission was
btained in about 70% of the patients in both treatment groups,r Disease 45 (2013) 969– 977
while histological remission was observed in 35% of patients in
the once daily group and in 41% of those in the twice daily group.
Endoscopy and histology revealed no statistically signiﬁcant dif-
ferences between the 2 dosing regimens. Prantera and colleagues
evaluated the therapeutic response to slow-release mesalazine
(MMx)  compared with topical 5-ASA in 79 patients with active left-
sided disease [72]. Endoscopic remission was  achieved by 45% of
the patients treated with MMx  and by 37% of those treated with
enemas. Histological remission (Floren score) [73] was obtained
in only 15% of the patients treated with MMx  and in 8% of the
patients treated with enema. Malchow and colleagues investigated
264 patients with active distal UC, treated with 5-ASA foam or
liquid enema [74]. After 4 weeks, in both treatment groups the over-
all remission rate was about 38%. Histological analysis showed an
improvement in both treatment groups (46% remission in the foam
group and 50% in the enema group).
Considering topical treatments, a trend in favour of mesalazine
as compared to steroids is observed; 295 patients presenting with a
relapse of distal UC were treated with 2 g mesalazine foam enema
or 20 mg  prednisolone foam enema [75]. After 4 weeks of treat-
ment, clinical remission was achieved by 52% of mesalazine-treated
patients and 31% of prednisolone-treated patients. Endoscopic
remission was  achieved in 40% of patients in the mesalazine group
and 31% in the steroid group. Similarly, mesalazine induced histo-
logical remission in 27% of the patients whereas the same effect
was induced in 21% of the steroid-treated patients.
4.2.2. Steroids
The capacity of corticosteroids to induce MH in UC patients is
well recognised [76]. The seminal paper by Truelove [77] showed
that hydrocortisone hemisuccinate sodium administered rectally
induces rapid clinical remission in patients with mild to mod-
erate UC. After 1 week of treatment patients showed a striking
improvement in terms of endoscopic and histological variables. The
steroid-treated group had a signiﬁcantly better histological appear-
ance after treatment as compared to baseline and to the placebo
group.
4.2.3. Immunomodulators
Data from a few studies suggest that azathioprine causes a
signiﬁcant degree of endoscopic healing and histological improve-
ment in the majority of CD patients. However, the rates of MH
using azathioprine vary among studies, probably due to differences
in the timing of endoscopy and the population considered. In an
open label study, Sandborn et al. demonstrated, for the ﬁrst time,
that a loading dose of intravenous azathioprine induced complete
endoscopic remission in 3 of 6 patients with active CD [78].
In a subsequent study, D’Haens et al. evaluated MH using aza-
thioprine in a cohort of 19 patients with recurrent postoperative
CD of the neoterminal ileum [79]. At least 6 months after com-
plete weaning from steroids, 15 patients (79%) achieved clinical
remission; in this group colonoscopy showed complete macro-
scopic healing of the neoterminal ileum in 6 patients. Comparison
of biopsy specimens taken before and after taking azathioprine
showed persistent mucosal architectural changes, with a complete
disappearance of the inﬂammatory inﬁltrate only in patients with
complete macroscopic healing.
The same authors examined a series of consecutive CD patients
with colitis and ileocolitis in clinical remission treated with aza-
thioprine for at least 9 months, and compared disease parameters
with pre-azathioprine data in the same patients [80]. The patients
had been previously treated with steroids for at least 3 years
and the ileocolonoscopy was performed less than 1 year before
the start of azathioprine. In this study a global histological CD
severity score was used [81]. This score combines active inﬂam-
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ells, polymorphonuclear cells, presence of erosions and/or ulcers,
ranulomas) and chronic architectural changes, and includes a cor-
ection factor for the proportion of biopsy specimens affected by
nﬂammation. The score ranged from 0 (normal) to 12 (severe
nﬂammation in all biopsies). The purely “inﬂammatory activity
core”, which ranges from 0 to 7, was calculated based on the
umber of inﬂammatory cells in the epithelium and the lamina
ropria. Complete endoscopic healing was observed in the colon
n 70% of the patients, and in 54% of the 13 patients with prior
leitis. Endoscopic healing was paralleled by a reduction in the
istological score, mainly due to a reduction in the inﬂamma-
ory inﬁltrate, but the latter was not always as “complete” as
uggested by the endoscopy. In the patients with complete endo-
copic healing, global histological scores decreased from 10 to 3;
nﬂammatory scores decreased from 5 to 2. In patients without
ndoscopic healing during azathioprine therapy, no signiﬁcant his-
ological changes were observed. In patients with ileal healing, the
icroscopic changes were more complete and the global histolog-
cal activity index decreased from a median of 7 to 2, whereas the
nﬂammatory component of the score decreased from 2 to 0.
More recently, it has been demonstrated that early adminis-
ration of azathioprine is effective not only in maintaining clinical
emission but also in inducing higher rates of MH  and histological
emission than steroids (budesonide), in patients with steroid-
ependent inﬂammatory Crohn’s ileocolitis or proximal colitis who
ad achieved clinical remission on conventional steroids [82]. In
his comparative study the primary endpoint was the rate of MH
nd histological remission of CD, and the average histology score
as calculated by dividing the sum of individual intestinal segmen-
al scores by the number of intestinal segments explored. At the
nd of 1-year treatment, 32 patients in the azathioprine group and
5 in the budesonide group were in clinical remission; complete
r nearly complete healing was achieved in 83% of azathioprine-
reated patients compared with only 24% of budesonide-treated
atients. In patients treated with azathioprine, MH  was associated
ith a signiﬁcant histological reduction of CD activity, although
omplete histological remission was not achieved. Moreover, the
istology score fell signiﬁcantly only in the azathioprine group, and
uch less improvement was observed in the budesonide group.
egarding the acute histological parameters (epithelial damage,
cute inﬂammatory cell inﬁltrate of the lamina propria, erosions
nd/or ulcers), an improvement of all of them was observed
egardless of disease location. The number of biopsies affected
as signiﬁcantly lower in azathioprine than budesonide-treated
atients (32% vs. 82%). The only histological parameters unaffected
y azathioprine were the glandular architecture and the presence
f chronic inﬂammation.
Only a few studies have investigated the effect of methotrexate
n mucosal healing in IBD patients. A pilot study that evaluated
he effects of adding this agent to standard treatment (steroids,
esalazine) in 14 CD patients with refractory disease, elicited a
ormal histology after 12 weeks of treatment in 4 patients [83].
nother study, comparing the effect of methotrexate with that of
zathioprine and inﬂiximab in 40 CD patients, did not show signiﬁ-
ant differences between the 3 groups after 3 months of treatment
84].
.2.4. Biological therapy
The development of biological agents for the treatment of CD
parked interest in the MH ﬁeld due to the potential alteration of the
isease course. Endoscopic and histological response to inﬂiximab
as investigated in a multicentre, randomised, double-blind, and
lacebo-controlled trial including 30 patients with active CD [85].
fter 4 weeks of intravenous administration of 5, 10, or 20 mg/kg of
nﬂiximab or placebo as a single infusion, the endoscopic improve-
ent was signiﬁcantly superior in inﬂiximab-treated patients asr Disease 45 (2013) 969– 977 975
compared to the placebo group. Histologically, a disappearance
of the inﬂammatory inﬁltrate was  observed only in inﬂiximab-
treated patients; however, cytoarchitectural changes persisted in
most patients.
These data were conﬁrmed by an immunohistological study
conducted in 15 patients with steroid-refractory CD treated with a
single infusion of inﬂiximab (5–20 mg/kg); 5 patients were treated
with placebo [86]. After 4 weeks of inﬂiximab, but not after placebo,
the total histological activity score was signiﬁcantly reduced in both
ileitis and colitis patients, and the total histological disease activity
decreased considerably, mainly due to the decrease in the inﬂam-
matory activity scores (reduction in the number of neutrophils in
the epithelium and lamina propria). Immunohistochemical stain-
ing showed a decrease of inﬂammatory reactions, and the number
of lamina propria mononuclear cells showed a global reduction of
CD4 and CD8 T lymphocytes and CD68 monocytes. In a small study
of 10 CD patients, the use of etanercept (another anti-TNF agent)
did not improve histological variables after 2 weeks [87].
Regarding biologicals, it is well known that anti-TNF therapy
can lead to MH in patients with UC [84,85], but to date histologi-
cal data are limited. A small study investigating 9 moderate-severe
UC patients treated for 10 weeks showed a signiﬁcant decrease
of the histological score only in responders (67% of the entire
group); however, histological normalisation was observed in only
30% of these [88]. In another study, ultrastructural colonic fea-
tures were studied in 7 UC patients before and after (2 weeks)
inﬂiximab treatment. After treatment, ultramicroscopic examina-
tion showed a morphological and functional improvement of the
epithelial organelles, rich mucus secretion, and recovery of the
chorionic components [89].
5. Conclusion
MH  is an important goal in CD and UC therapy, and is associated
with a reduced disease progression and improved quality of life.
Moreover, it is an important factor (especially since the advent of
biological therapies) in the reduction of the risk of colorectal malig-
nancies in UC [22]. Ileocolonoscopy has become the gold standard
in the management of inﬂammatory bowel disease and can be used
to support therapeutic decision-making. At present, the endoscopic
deﬁnition of MH  is considered to be the absence of all ulcera-
tions and inﬂammation, even though the use of several different
endoscopic scoring systems, with different cutoff values, leads to
differences in MH  rates. Identifying cutoff values to distinguish
the endoscopic response to treatments should enable endoscopic
scores to be used in clinical practice to evaluate MH  as a parameter
of remission or relapse.
In terms of future research, it is important to establish the
value of endoscopy as a means of guiding therapeutic changes
and decision-making, to continue or stop therapy, or to switch
to another treatment. Endoscopic re-evaluation should be used to
identify non-responder patients, in whom an increased dosage,
anticipated administration, or use of other drugs should be
attempted. Furthermore, to improve the follow-up of IBD patients,
it should be established whether histology should be included in
the deﬁnition of MH.  Since ileocolonoscopy in CD evaluates only
the lower gastrointestinal tract, wireless capsule endoscopy must
be considered to assess MH  in the upper gastrointestinal tract.
Moreover, as shown in Table 2, analysis of the published studies
on biological agents demonstrates that different factors affect the
rate of MH:  (i) the deﬁnition of MH;  (ii) the type of biological drug
and other associated medications; (iii) the duration of treatment.
The timing of the endoscopic evaluation and a proper deﬁnition
of MH  need to be deﬁned in prospective studies. To date, MH  in
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istological, endoscopic and clinical data exist, but are rarely
ssessed in therapeutic trials. This poses a problem, since normal
linical, serological and endoscopic ﬁndings are not indicative of
istological absence of disease activity. Thus, it is important and
dvisable to plan future studies that also feature, as a key element,
 comparison between endoscopic and histological variables.
onﬂict of interest statement
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